Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of APR Applied Pharma Research.

    Client Virtual Booth

    APR APPLIED PHARMA RESEARCH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    APR Applied Pharma Research
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Via Corti 5 Balerna, (TI) 6828, CH
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.apr.ch/applied-pharma-research/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/apr-applied-pharma-research-s-a-?trk=tyah&trkInfo=tas%3AAPR%20APPL
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR

    Details:

    Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides a commercial infrastructure foundation for future product launches.


    Lead Product(s): Amino Acids Mixture,Minerals,Vitamins

    Therapeutic Area: Genetic Disease Product Name: PKU Golike

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Relief Therapeutics

    Deal Size: $72.2 million Upfront Cash: $23.3 million

    Deal Type: Acquisition June 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)

    Details:

    First mix of amino acids having a pharmacological primary mode of action designed to reduce and control Phenylalanine fluctuations.


    Lead Product(s): APR-OD031

    Therapeutic Area: Genetic Disease Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 26, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search